Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
Holding ELDN?
Track your performance easily

Eledon Pharmaceuticals (ELDN) Income Statement

779 Followers

Eledon Pharmaceuticals Income Statement

Last quarter (Q2 2024), Eledon Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Eledon Pharmaceuticals's net income was $-44.91M. See Eledon Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 46.91M$ 43.00M$ 39.78M$ 36.87M$ 18.46M$ 14.18M
Operating Income
$ -46.91M$ -43.00M$ -88.43M$ -36.87M$ -18.46M$ -14.18M
Net Non Operating Interest Income Expense
------
Other Income Expense
$ 2.34M$ 2.67M$ -48.19M$ -7.00K$ -79.00K$ -40.00K
Pretax Income
$ -43.90M$ -40.33M$ -87.97M$ -36.86M$ -23.21M$ -16.01M
Tax Provision
---$ -2.35M$ -404.00K$ -38.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -75.18M$ -40.33M$ -87.97M$ -34.51M$ -22.81M$ -16.01M
Basic EPS
$ -3.09$ -4.73$ -6.16$ -2.33$ -15.72-
Diluted EPS
$ -3.09$ -4.73$ -6.16$ -2.33$ -15.72$ -24.48
Basic Average Shares
$ 132.45M$ 24.62M$ 14.29M$ 14.82M$ 1.45M$ 655.53K
Diluted Average Shares
$ 132.45M$ 24.62M$ 14.29M-$ 1.45M$ 655.53K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 46.91M$ 43.00M$ 39.78M$ 36.87M$ 18.46M$ 14.18M
Net Income From Continuing And Discontinued Operation
$ -75.18M$ -40.33M$ -87.97M$ -34.51M$ -22.81M$ -16.01M
Normalized Income
$ -31.29M$ -31.86M-$ -39.21M--
Interest Expense
------
EBIT
$ -76.03M$ -43.00M$ -39.78M$ -36.87M$ -16.18M$ -16.01M
EBITDA
$ -75.65M$ -42.63M$ -39.41M$ -36.67M$ -16.00M$ -15.83M
Currency in USD

Eledon Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis